1. Esenvia® Product License. Stragen Pharma. April 30th, 2015.
  2. Natural Medicines Comprehensive Database – Online. Diosmin Monograph. Accessed September 26, 2013.
  3. Maruszynski M et al. A double blind, randomized study evaluating the influence of semi-synthetic diosmin, and a purified, micronized flavonoid fraction (diosmin and hesperdin), on symptoms of chronic venous insufficiency of the lower limb: a four-week observation. Przeglad Flebologiczny 2004;12(2).
  4. Pokrowsky AV. Results of a multicentre clinical trial on the effectiveness and safety of VASOKET in patients with varicose veins and chronic venous insufficiency. Angiology Vasc Surgery 2011; 17(4):8-13.
  5. Batchvarov IV et al. One-year Diosmin therapy (600 mg) in patients with chronic venous insufficiency: results and analysis. J Biomed Clin Res 2010;3(1):51-4.
  6. Savineau JP, Marthans R. Diosmin-induced increase in sensitivity to Ca2+ of the smooth muscle contractile apparatus in the rat isolated femoral vein. Br J Pharmacol 1994;111:978-80.
  7. Melin AM et al. In vivo effect of diosmin on carrageenau and CCl4-induced lipid peroxidation in rat liver microsomes. J Biochem Toxicol 1996;11:27-32.
  8. Casley-Smith JR, Casley-Smith JR. The effect of diosmin (a benzo-pyrone) upon some high-protein oedemas: lung contusion, and burn and lymphoedema of rat legs. Agents Actions 1985;17: 14-20.
  9. Manthey JA. Biological properties of flavonoids pertaining to inflammation. Microcirculation 2000;7(6 Pt 2):S29-34.
  10. Casley-Smith JR. Changes in the microcirculation at the superficial and deeper levels in lymphoedema: the effects and results of massage, compression, exercise and benzopyrones on these levels during treatment. Clin Hemorheol Microcirc 2000;23:335-43.
  11. Maksimovic ZV et al. Medicamentous treatment of chronic venous insufficiency using semisynthetic diosmin: a prospective study. Acta Chir Iugosl 2008;55(4):53-9.
  12. Gloviczki P et al. Review and comment of the 2011 Clinical Practice Guidelines of the Society for Vascular Surgery and the American Venous Forum. Phlebology 2012;19:107-20.
  13. Carpentier PH, Mathieu M. Évaluation de l’efficacité Clinique d’un médicament veinotrope: les enseignements d’un essai thérapeutique avec la diosmine d’hémisynthese dans le syndrome des jambes lourdes. J Mal Vasc 1998;23 :106-12.
  14. Cleveland Clinic. Chronic venous insufficiency. Available at: Accessed July 11, 2016
  15. Vascular Disease Foundation. Chronic venous insufficiency. Available at: Accessed October 6, 2014.
  16. MedicineNet. Varicose veins. Available at: Accessed November 16, 2014.
  17. MedicineNet. Spider veins. Available at: Accessed November 16, 2014.
  18. Henry F et al. Jambes lourdes et microangiopathie de stase: approches préventives et thérapeutiques. Rev Med Liege 2003;58 (6):435-8.
  19. Callosum. Qualitative research with patients about CVI. June 2014.
  20. Chiesa R et al. Effect of chronic venous insufficiency on activities of daily living and quality of life: correlation of demographic factors with duplex ultrasonography findings. Angiology 2007;58(4):440-9.
  21. Merriam-Webster. Flavonoid. Available at:
  22. MedLine Plus. Vascular diseases. Available at:
  23. Encyclopedia Britannica. Lymphatic system. Available at:
  24. Merriam-Webster. Venous. Available at:
  25. Callosum. Exploring consumers’ usage habits and general attitudes. August 2014.
  26. Henriet JP. Insuffisance veineuse fonctionnelle: essai comparatif d’une seule prise par jour de Diovenor 600 mg versus 2 prises par jour d’un mélange de 500 mg de flavonoides (900 mg de diosmine). Phlébologie 1995;8 :1-7.
  27. Canadian Society of Vascular Nursing . Available at: Newsletter March 25.pdf
  28. US National Library of Medicine National Institutes of Health.. Available at :
  29. Live Strong. Available at: http://wwwtarget="_blank"
  30. Medscape. Available at: – d8